Literature DB >> 16466034

Diagnosing smear-negative tuberculosis using case definitions and treatment response in HIV-infected adults.

D Wilson1, J Nachega, C Morroni, R Chaisson, G Maartens.   

Abstract

OBJECTIVE: To assess the diagnostic utility of expanded case definitions for HIV-associated smear-negative pulmonary tuberculosis (PTB) and extra-pulmonary TB (EPTB), and to derive objective criteria for response to anti-tuberculosis treatment.
DESIGN: A prospective cohort study of HIV-infected adults who met expanded clinical case definitions for smear-negative PTB and EPTB.
METHODS: All participants were started on rifampicin-based anti-tuberculosis treatment after mycobacterial cultures from multiple sites. At weeks 2, 4 and 8, response to treatment (RTT) was assessed by measuring changes in weight, haemoglobin, C-reactive protein, Karnofsky performance score and symptom count ratio.
RESULTS: Of 147 participants enrolled, 105 (71%) were diagnosed with definite (culture-positive) or probable (histological features) TB and 25 (17%) with possible TB (treatment response). The positive predictive value for the most common case definitions ranged from 89% to 96%. Significant improvements in all the RTT parameters occurred in the subjects with confirmed TB (P < 0.001). Clinically relevant RTT criteria were derived, two or more of which were met at week 8 in 97.5% of subjects with confirmed TB, 91.3% of subjects with possible TB and none of the subjects without TB.
CONCLUSION: Expanded case definitions could enhance the diagnosis of PTB and EPTB in HIV-infected adults in resource-limited settings. Using objective criteria, RTT can be assessed within 8 weeks of initiating anti-tuberculosis treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16466034

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  33 in total

1.  Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel.

Authors:  Stephen M Graham; Tahmeed Ahmed; Farhana Amanullah; Renee Browning; Vicky Cardenas; Martina Casenghi; Luis E Cuevas; Marianne Gale; Robert P Gie; Malgosia Grzemska; Ed Handelsman; Mark Hatherill; Anneke C Hesseling; Patrick Jean-Philippe; Beate Kampmann; Sushil Kumar Kabra; Christian Lienhardt; Jennifer Lighter-Fisher; Shabir Madhi; Mamodikoe Makhene; Ben J Marais; David F McNeeley; Heather Menzies; Charles Mitchell; Surbhi Modi; Lynne Mofenson; Philippa Musoke; Sharon Nachman; Clydette Powell; Mona Rigaud; Vanessa Rouzier; Jeffrey R Starke; Soumya Swaminathan; Claire Wingfield
Journal:  J Infect Dis       Date:  2012-03-22       Impact factor: 5.226

2.  Diagnostic accuracy and clinical role of rapid C-reactive protein testing in HIV-infected individuals with presumed tuberculosis in South Africa.

Authors:  P K Drain; L Mayeza; P Bartman; R Hurtado; P Moodley; S Varghese; G Maartens; G G Alvarez; D Wilson
Journal:  Int J Tuberc Lung Dis       Date:  2014-01       Impact factor: 2.373

Review 3.  Diagnostic accuracy of C-reactive protein for active pulmonary tuberculosis: a meta-analysis.

Authors:  C Yoon; L H Chaisson; S M Patel; I E Allen; P K Drain; D Wilson; A Cattamanchi
Journal:  Int J Tuberc Lung Dis       Date:  2017-09-01       Impact factor: 2.373

4.  Diagnostic accuracy of the microscopic observation drug susceptibility assay: a pilot study from India.

Authors:  J S Michael; P Daley; S Kalaiselvan; A Latha; J Vijayakumar; D Mathai; K R John; M Pai
Journal:  Int J Tuberc Lung Dis       Date:  2010-04       Impact factor: 2.373

5.  Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis.

Authors:  Marco Schito; Trevor F Peter; Sean Cavanaugh; Amy S Piatek; Gloria J Young; Heather Alexander; William Coggin; Gonzalo J Domingo; Dennis Ellenberger; Eugen Ermantraut; Ilesh V Jani; Achilles Katamba; Kara M Palamountain; Shaffiq Essajee; David W Dowdy
Journal:  J Infect Dis       Date:  2012-03-29       Impact factor: 5.226

6.  Sputum induction to aid diagnosis of smear-negative or sputum-scarce tuberculosis in adults in HIV-endemic settings.

Authors:  Jonathan G Peter; Grant Theron; Nevanda Singh; Avani Singh; Keertan Dheda
Journal:  Eur Respir J       Date:  2013-03-21       Impact factor: 16.671

7.  Clinical and radiographic factors do not accurately diagnose smear-negative tuberculosis in HIV-infected inpatients in Uganda: a cross-sectional study.

Authors:  J Lucian Davis; William Worodria; Harriet Kisembo; John Z Metcalfe; Adithya Cattamanchi; Michael Kawooya; Rachel Kyeyune; Saskia den Boon; Krista Powell; Richard Okello; Samuel Yoo; Laurence Huang
Journal:  PLoS One       Date:  2010-03-26       Impact factor: 3.240

8.  Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples.

Authors:  Keertan Dheda; Virginia Davids; Laura Lenders; Teri Roberts; Richard Meldau; Daphne Ling; Laurence Brunet; Richard van Zyl Smit; Jonathan Peter; Clare Green; Motasim Badri; Leonardo Sechi; Surendra Sharma; Michael Hoelscher; Rodney Dawson; Andrew Whitelaw; Jonathan Blackburn; Madhukar Pai; Alimuddin Zumla
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

9.  Comparison of two methods for acquisition of sputum samples for diagnosis of suspected tuberculosis in smear-negative or sputum-scarce people: a randomised controlled trial.

Authors:  Jonathan G Peter; Grant Theron; Anil Pooran; Johnson Thomas; Mellissa Pascoe; Keertan Dheda
Journal:  Lancet Respir Med       Date:  2013-07-19       Impact factor: 30.700

10.  Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study.

Authors:  P Daley; J S Michael; P Hmar; A Latha; P Chordia; D Mathai; K R John; M Pai
Journal:  Int J Tuberc Lung Dis       Date:  2009-08       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.